Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can an ancient herbal brew tame the deadliest pancreatitis?

NCT ID NCT07816900

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Severe acute pancreatitis causes the pancreas to swell dangerously, and pressure building inside the abdomen can lead to organ failure. Researchers at a Shanghai hospital are testing whether adding Da-Cheng-Qi Decoction, a classic Chinese herbal formula, to standard Western treatment lowers that pressure faster than standard care alone. Sixty adults with severe acute pancreatitis and high abdominal pressure receive either the herbal formula through a stomach tube plus standard care, or standard care by itself. The team tracks abdominal pressure every 12 hours for a week, along with stool output, hospital and ICU stays, and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Da-Cheng-Qi Decoction, a traditional Chinese herbal formula given through a stomach tube alongside standard hospital care
What this could lead to
If it helps, this could offer a low-cost herbal add-on that eases dangerous abdominal pressure and shortens hospital stays for people with severe acute pancreatitis.
What could go wrong
The trial is small, single-center, and enrolls only 60 people, so any benefit may not hold up in larger studies. Herbal formulas can also interact with other drugs or cause digestive side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Apr 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Severe acute pancreatitis diagnosed according to the revised Atlanta classification * Age 18-80 years * Disease onset within 72 h * Intra-abdominal hypertension (IAP \>= 12 mmHg) within 24 h of admission * Written informed consent obtained Exclusion Criteria: * Age \<18 or \>80 years * Pregnancy or lactation * Advanced malignancy (pancreatic, hepatobiliary, or gastrointestinal) * Severe chronic organ failure * Autoimmune disease or immunosuppression * Intra-abdominal hemorrhage * Urinary tract infection or prior bladder surgery (precluding bladder manometry) * Allergic constitution or known allergy to study medication * Psychiatric illness

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intra-abdominal hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emergency Department, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.